Dalya Güriş

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

31h-index7.7kcitations64works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Clostridium difficile and Clostridium perfringens research(16), Herpesvirus Infections and Treatments(14), Virology and Viral Diseases(14), Microscopic Colitis(12), Cervical Cancer and HPV Research(11)

Publications64 total

Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial
EBioMedicine·2022· 24 citedOpen Access
Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously
Human Vaccines & Immunotherapeutics·2022· 3 citedOpen Access
In RRP, serologic response to HPV is frequently absent and slow to develop
PLoS ONE·2020· 14 citedOpen Access
Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing
Anaerobe·2019· 8 cited
Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection
Clinical Infectious Diseases·2019· 24 citedOpen Access
Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II
Open Forum Infectious Diseases·2019· 10 citedOpen Access
Efficacy of bezlotoxumab based on timing of administration relative to start of antibacterial therapy for Clostridium difficile infection
Journal of Antimicrobial Chemotherapy·2018· 22 citedOpen Access
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Clinical Infectious Diseases·2018· 200 citedOpen Access
Endogenous Serum IgG Antibodies to Toxin B Are Associated with Protection against Infection Recurrence.
Open Forum Infectious Diseases·2017Open Access
Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial
Journal of Antimicrobial Chemotherapy·2017· 70 citedOpen Access
Efficacy of Bezlotoxumab in Patients with Recurrent Clostridium Difficile Infection (CDI): Pooled Analysis of Data from the Modify Trials
Gastroenterology·2017
Bezlotoxumab for Prevention of Recurrent <i>Clostridium difficile</i> Infection
New England Journal of Medicine·2017· 832 citedOpen Access
Endogenous Serum IgG Antibodies to Clostridium difficile Toxin B Are Associated with Protection against C. difficile Infection Recurrence
Open Forum Infectious Diseases·2017Open Access
Bezlotoxumab (BEZ) for Prevention of Clostridium difficile Infection (CDI) Recurrence (rCDI): Distinguishing Relapse from Reinfection with Whole Genome Sequencing (WGS)
Open Forum Infectious Diseases·2017Open Access
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
Open Forum Infectious Diseases·2017· 71 citedOpen Access
Antibodies to Toxin B Are Protective Against<i>Clostridium difficile</i>Infection Recurrence
Clinical Infectious Diseases·2016· 71 citedOpen Access
599 The Monoclonal Antibody, Bezlotoxumab Targeting C. difficile Toxin B Shows Efficacy in Preventing Recurrent C. difficile Infection (CDI) in Patients at High Risk of Recurrence or of CDI-Related Adverse Outcomes
Gastroenterology·2016· 7 cited
Efficacy of Bezlotoxumab in Patients Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridium difficile Infection (CDI)
Open Forum Infectious Diseases·2016· 3 citedOpen Access
Bezlotoxumab Alone and With Actoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients on Standard of Care Antibiotics: Integrated Results of 2 Phase 3 Studies (MODIFY I and MODIFY II)
Open Forum Infectious Diseases·2015· 18 citedOpen Access
Incidence, Clearance, and Disease Progression of Genital Human Papillomavirus Infection in Heterosexual Men
The Journal of Infectious Diseases·2014· 53 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Edson Duarte Moreira(9), Scott Vuocolo(9), Richard M. Haupt(9), Anna R. Giuliano(8), Joel M. Palefsky(8), Marcus Dörr(8), Heiko Jessen(7), Stephen E. Goldstone(6), Richard J. Hillman(6), Jane F. Seward(6), Elizabeth Garner(6), Carlos Aranda(5), Eftyhia Vardas(5), J. Brooke Marshall(5), Dale N. Gerding(5), Ciarán P. Kelly(5), Galia Rahav(5), Karen Eves(5), Nicholas A. Kartsonis(5), Daron Ferris(4)